Studies show that 9.2% of Taxotere patients experienced hair loss for up to 10 years, and sometimes longer. If you received Taxotere during breast cancer treatment and experienced hair loss for longer than 6 months, you may be entitled to financial compensation.
Consumers are claiming that the manufacturer knew that Taxotere could cause permanent or semi-permanent hair loss and chose not to disclose the details. Now they are suing the manufacturer for negligence and withholding critical information.
Time is limited! Fill out the form on this page to see if you qualify.
An advocate or attorney will contact you within minutes for your free consultation.
No fees unless you are awarded compensation!
Taxotere is mitotic inhibitor that stops cancer cells from dividing. The cancer cells then fill up with microtubule fibers and die. Taxotere is used to treat several forms of cancer, including breast cancer, non-small cell lung cancer, advanced stomach cancer, head and neck cancer, and metastatic prostate cancer. Taxotere is manufactured by Sanofi in the United States. Its generic name is docetaxel.
On March 10, 2016, lawyers filed the first lawsuit against Sanofi (manufacturer of Taxotere) in Illinois Federal Court on behalf of Ms. Erma Spann. The complaint states that Ms. Spann suffers from “permanent disfiguring hair loss” after receiving Taxotere during her breast cancer treatment following her partial mastectomy in 2005.
Women could have chosen other chemotherapy options, but the manufacturer took away their ability to make informed decisions by not fully disclosing the significant side effects. Lawsuits are now beginning to be filed against Sanofi. If you have suffered semi-permanent or permanent hair loss after receiving Taxotere during breast cancer treatment, you may qualify to get payment from the manufacturer. Get a free, quick evaluation right here today.
